Results 11 to 20 of about 14,898,836 (369)
The B-team: Equal but different?
The Journal of Haemophilia Practice, 2021 As a person with haemophilia B, I have known there are differences between haemophilia A and haemophilia B and their respective treatment throughout my life – though I was shocked when I learnt about the impact inhibitors can have when it comes to ...
Pembroke Luke
doaj +1 more source
TH Open, 2022 In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term ...
Tine M.H.J. Goedhart +13 more
doaj +1 more source
The Journal of Haemophilia Practice, 2021 Current treatment for severe haemophilia includes prophylactic factor replacement to prevent bleeding. Coagulation factor products have significant inter-patient variability in pharmacokinetic (PK) parameters.
Kwan Celia +5 more
doaj +1 more source
A Case of Heel Reconstruction with a Reverse Sural Artery Flap in a Hemophilia B Patient
Archives of Plastic Surgery, 2012 Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing.
Byung Kwon Lee, Jeong Su Shim
doaj +1 more source
Molecular Therapy: Methods & Clinical Development, 2019 Gene therapy for severe hemophilia B is advancing and offers sustained disease amelioration with a single treatment. We have reported the efficacy and safety of AMT-060, an investigational gene therapy comprising an adeno-associated virus serotype 5 ...
Elisabeth A. Spronck +10 more
doaj +1 more source
X-Ray Determination of the Variable Rate of Mass Accretion onto TW Hydrae [PDF]
, 2012 Diagnostics of electron temperature (T_e), electron density (n_e), and hydrogen column density (N_H) from the Chandra High Energy Transmission Grating spectrum of He-like Ne IX in TW Hydrae (TW Hya), in conjunction with a classical accretion model, allow
Brickhouse, N. S. +5 more
core +2 more sources
Reports, 2020 This study aimed to identify the characteristics of patients with hemophilia B eligible for once-weekly treatment with Nonacog alfa. Methods: A survey was conducted in 14 Hemophilia (HCs) of Italy.
Dorina Cultrera +14 more
doaj +1 more source
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
RENAL ALLOGENEIC TRANSPLANTATION IN PATIENT WITH HAEMOPHILIA B
Вестник трансплантологии и искусственных органов, 2014 We report the case of successful renal allogeneic transplantation and treatment in a 56-year-old patient with haemophilia B at Hematology Research Center. He has received replacement therapy by factor IX since 2010.
N. V. Purlo +4 more
doaj +1 more source
Case Reports in Transplantation, 2020 Herein, we discuss a case of a 39-year-old male with hemophilia B, who developed end-stage liver disease secondary to nonalcoholic steatohepatitis, that underwent orthotopic liver transplantation (OLT) as a curative means for his liver disease and ...
Jesse E. Harris +3 more
doaj +1 more source